Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Zydus receives final approval from USFDA for Theophylline ER Tablets

Theophylline is used to treat asthma and chronic obstructive pulmonary disease

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

LVPEI observes World Glaucoma Week

Vision loss due to Glaucoma can be prevented if it is detected and treated early

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody

100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh

Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union